Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Jun 3

PMID 28573138

Citations 13

Authors

Michele Fornaro

Domenico de Berardis

Giampaolo Perna

Marco Solmi

Nicola Veronese

Laura Orsolini

Elisabetta Filomena Buonaguro

Felice Iasevoli

Cristiano Andre Kohler

Andre Ferrer Carvalho

Andrea de Bartolomeis

Affiliations

Soon will be listed here.

Abstract

Introduction: A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic.

Methods: Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception until October 2016.

Results: Twelve included systematic reviews were of moderate-to-high quality and consistent in covering the handful of RCTs available to date, suggesting the promising efficacy, safety, and tolerability profile of lurasidone. Concordance on the drug profile seems to be corroborated by a steadily increasing number of convergent qualitative reports on the matter.

Limitations: Publication, sponsorship, language, citation, and measurement biases.

Conclusions: Despite being preliminary in nature, this overview stipulates the effectiveness of lurasidone in the acute treatment of Type I bipolar depression overall. As outlined by most of the reviewed evidence, recommendations for future research should include further controlled trials of extended duration.

Citing Articles

Unraveling the Complex Interplay Between Neuroinflammation and Depression: A Comprehensive Review.

Salcudean A, Popovici R, Pitic D, Sarbu D, Boroghina A, Jomaa M Int J Mol Sci. 2025; 26(4).

PMID: 40004109 PMC: 11855341. DOI: 10.3390/ijms26041645.

Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis.

Lin Y, Chen Y, Hung K, Liang C, Tseng P, Carvalho A BMJ Ment Health. 2024; 27(1).

PMID: 39557452 PMC: 11574478. DOI: 10.1136/bmjment-2024-301165.

Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis.

Guarro Carreras M, Jimenez Suarez L, Lago Garcia L, Montes Reula L, Neyra Del Rosario A, Rodriguez Batista F Drugs Context. 2024; 13.

PMID: 39131604 PMC: 11313206. DOI: 10.7573/dic.2024-4-4.

Improving Quality of Life in Bipolar Disorders with an Immersive Virtual Reality Remediation Training Randomized Controlled Trial (RCT).

Primavera D, Migliaccio G, Garau V, Orru G, Scano A, Perra A J Clin Med. 2024; 13(13).

PMID: 38999451 PMC: 11242424. DOI: 10.3390/jcm13133886.

Lurasidone as add-on to fluoxetine in obsessive-compulsive disorder with comorbid restrictive anorexia: a case report.

Orsolini L, Bellagamba S, Volpe U Int Clin Psychopharmacol. 2023; 39(3):211-214.

PMID: 37556307 PMC: 10965133. DOI: 10.1097/YIC.0000000000000502.

References

McIntyre R, Cha D, Alsuwaidan M, McIntosh D, Powell A, Jerrell J . A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother. 2012; 13(11):1653-9. DOI: 10.1517/14656566.2012.683174. View

Fountoulakis K, Kelsoe J, Akiskal H . Receptor targets for antidepressant therapy in bipolar disorder: an overview. J Affect Disord. 2011; 138(3):222-38. DOI: 10.1016/j.jad.2011.04.043. View

Pacchiarotti I, Bond D, Baldessarini R, Nolen W, Grunze H, Licht R . The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170(11):1249-62. PMC: 4091043. DOI: 10.1176/appi.ajp.2013.13020185. View

Rajagopalan K, Bacci E, Wyrwich K, Pikalov A, Loebel A . The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. Int J Bipolar Disord. 2016; 4(1):7. PMC: 4792823. DOI: 10.1186/s40345-016-0049-1. View

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll C . Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012; 26(9):733-59. DOI: 10.2165/11634500-000000000-00000. View

Sudhir Kumar C, Frangou S . Clinical implications of cognitive function in bipolar disorder. Ther Adv Chronic Dis. 2012; 1(3):85-93. PMC: 3513860. DOI: 10.1177/2040622310374678. View

Carta M, Moro M, Nardi A, Calabrese J . Potential use of lurasidone for the treatment of bipolar psychosis. Expert Opin Investig Drugs. 2015; 24(4):575-84. DOI: 10.1517/13543784.2015.1009976. View

Zohar J, Stahl S, Moller H, Blier P, Kupfer D, Yamawaki S . A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015; 25(12):2318-25. DOI: 10.1016/j.euroneuro.2015.08.019. View

Dodd S, Fernandes B, Dean O . Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder. Curr Neuropharmacol. 2015; 13(5):656-62. PMC: 4761635. DOI: 10.2174/1570159x13666150630175841. View

10.

Sanford M, Dhillon S . Lurasidone: a review of its use in adult patients with bipolar I depression. CNS Drugs. 2015; 29(3):253-63. DOI: 10.1007/s40263-015-0234-2. View

11.

Greenberg W, Citrome L . Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clin Pharmacokinet. 2016; 56(5):493-503. DOI: 10.1007/s40262-016-0465-5. View

12.

Zubieta J, Alessi N . Is there a role of serotonin in the disruptive behavior disorders? A literature review. J Child Adolesc Psychopharmacol. 2009; 3(1):11-35. DOI: 10.1089/cap.1993.3.11. View

13.

Kung J, Chiappelli F, Cajulis O, Avezova R, Kossan G, Chew L . From Systematic Reviews to Clinical Recommendations for Evidence-Based Health Care: Validation of Revised Assessment of Multiple Systematic Reviews (R-AMSTAR) for Grading of Clinical Relevance. Open Dent J. 2010; 4:84-91. PMC: 2948145. DOI: 10.2174/1874210601004020084. View

14.

Chiu Y, Ereshefsky L, Preskorn S, Poola N, Loebel A . Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014; 29(3):191-202. DOI: 10.1515/dmdi-2014-0005. View

15.

Keks N, Hope J, Castle D . Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?. Australas Psychiatry. 2016; 24(3):289-91. DOI: 10.1177/1039856216641309. View

16.

Gao K, Yuan C, Wu R, Chen J, Wang Z, Fang Y . Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. Neurosci Bull. 2015; 31(5):572-88. PMC: 5563672. DOI: 10.1007/s12264-014-1534-0. View

17.

Mnie-Filali O, Lambas-Senas L, Scarna H, Haddjeri N . Therapeutic potential of 5-HT7 receptors in mood disorders. Curr Drug Targets. 2009; 10(11):1109-17. DOI: 10.2174/138945009789735129. View

18.

Ketter T, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A . LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depress Anxiety. 2016; 33(5):424-34. PMC: 5069590. DOI: 10.1002/da.22479. View

19.

Burdick K, Ketter T, Goldberg J, Calabrese J . Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry. 2015; 76(3):e342-50. PMC: 4472380. DOI: 10.4088/JCP.14cs09399. View

20.

Schaffer C, Schaffer L, Nordahl T, Stark N, Gohring C . An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder. J Clin Psychopharmacol. 2015; 36(1):88-9. DOI: 10.1097/JCP.0000000000000450. View